Diasorin | DIA

Stock Price
104.80
Daily Change
-1.60 -1.50%
Monthly
4.86%
Yearly
23.82%
Q1 Forecast
105.04



Peers Price Chg Day Year Date
Amplifon 25.72 -0.37 -1.42% -13.84% Jan/24
Avanos Medical 15.81 0.01 0.06% -19.50% Jan/24
Brookdale Senior Living 4.92 0 0% -14.14% Jan/24
Cencora 248.47 0.68 0.27% 14.30% Jan/24
Diasorin 104.80 -1.60 -1.50% 23.82% Jan/24
Encompass Health 95.65 0.38 0.40% 34.36% Jan/24
Enovis 47.79 0.52 1.10% -19.78% Jan/24
GE HealthCare Technologies 88.67 0.51 0.58% 21.68% Jan/24
OPKO Health 529.00 1.00 0.19% 39.17% Jan/23
Zimmer Biomet Holdings 110.87 1.15 1.05% -8.01% Jan/23

Indexes Price Day Year Date
IT40 36201 87.88 0.24% 20.04% Jan/24
EU600 530 -0.26 -0.05% 10.77% Jan/24

Diasorin traded at 104.80 this Friday January 24th, decreasing 1.60 or 1.50 percent since the previous trading session. Looking back, over the last four weeks, Diasorin lost 4.86 percent. Over the last 12 months, its price rose by 23.82 percent. Looking ahead, we forecast Diasorin to be priced at 105.04 by the end of this quarter and at 102.29 in one year, according to Trading Economics global macro models projections and analysts expectations.

DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.